anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

215,521-215,580 of 319,975

filter-aware
26
Uses a nested circle diagram to show market segmentation and penetration.Sonos | Results Presentation Deck | 33 slides · Sonos
Conference presentation Investor relations 1 hit
27
Uses a chevron-style arrow to indicate progression from current state to future state.Sonos | Results Presentation Deck | 33 slides · Sonos
Conference presentation Investor relations 1 hit
28
The slide tracks the shift in revenue mix towards higher-margin channels.Sonos | Results Presentation Deck | 33 slides · Sonos
Conference presentation Investor relations 1 hit
29
Includes non-GAAP financial measures and constant currency growth rates.Sonos | Results Presentation Deck | 33 slides · Sonos
Conference presentation Investor relations 1 hit
30
Sonos | Results Presentation Deck | 33 slidesSonos | Results Presentation Deck | 33 slides · Sonos
Conference presentation Investor relations 1 hit
31
Financial data in thousands, unaudited. Includes detailed footnotes explaining legal/transaction costs and restructuring/abandonment costs.Sonos | Results Presentation Deck | 33 slides · Sonos
Conference presentation Investor relations 1 hit
32
Includes footnotes explaining legal/transaction costs and the 2023 restructuring plan.Sonos | Results Presentation Deck | 33 slides · Sonos
Conference presentation Investor relations 1 hit
33
Note: $ in thousands, unaudited.Sonos | Results Presentation Deck | 33 slides · Sonos
Conference presentation Investor relations 1 hit
01
Slide 1
Theravance Biopharma | Results Presentation Deck | 35 slidesTheravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Attention1 hit
02
Theravance Biopharma | Results Presentation Deck | 35 slidesTheravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Attention1 hit
03
Theravance Biopharma | Results Presentation Deck | 35 slidesTheravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Attention1 hit
04
The slide uses a three-column layout to categorize strategic priorities.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Attention1 hit
05
Theravance Biopharma | Results Presentation Deck | 35 slidesTheravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Attention1 hit
06
Slide serves as a product introduction/cover slide for a corporate presentation.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Need1 hit
07
Theravance Biopharma | Results Presentation Deck | 35 slidesTheravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Need1 hit
08
The slide shows two line charts tracking market share growth in different care settings.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Need1 hit
09
The slide highlights consistent growth in both metrics, with Q/Q growth percentages annotated above each bar.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Need1 hit
10
Uses a Venn diagram to illustrate the patient segments (Dexterity Challenges, Cognitive Impairment, Suboptimal PIFR) that define the addressable population.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
11
Theravance Biopharma | Results Presentation Deck | 35 slidesTheravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
12
The slide outlines a clinical trial methodology using a timeline-based study design.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
13
The slide illustrates how findings from one study (PIFR-1) informed the design of a subsequent study (PIFR-2) by narrowing the patient population to GOLD 3/4, resulting in statistically significant improvement.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
14
Theravance Biopharma | Results Presentation Deck | 35 slidesTheravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
15
The slide outlines a clinical trial design using a randomized withdrawal methodology.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
16
The slide uses a combination of a market sizing summary at the top and a competitive landscape table at the bottom.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
17
The slide uses a classic 'problem vs. solution' or 'market gap vs. strategic imperative' structure.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
18
Theravance Biopharma | Results Presentation Deck | 35 slidesTheravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Satisfaction1 hit
19
Includes GAAP and non-GAAP financial measures.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Action1 hit
20
The slide provides a standard financial reconciliation table.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Action1 hit
21
The slide includes specific footnotes regarding non-GAAP adjustments and share buyback activity.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Action1 hit
22
The chart shows a significant reduction in operating expenses from 2020 to 2023.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Action1 hit
23
Theravance Biopharma | Results Presentation Deck | 35 slidesTheravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Action1 hit
24
The table displays projected royalties, net sales, and milestone payments from 2023 to 2026.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Action1 hit
25
Uses a curved arrow diagram to represent a progression or portfolio of value drivers.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Action1 hit
26
Theravance Biopharma | Results Presentation Deck | 35 slidesTheravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
27
Standard pharmaceutical product disclosure slide.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
28
Includes a footnote referencing market research methodology.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
29
Theravance Biopharma | Results Presentation Deck | 35 slidesTheravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
30
Includes definitions for COPD, nOH, and PTE in the footer.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
31
The slide uses a mathematical equation format to explain the revenue recognition process.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
32
The slide uses a split-panel layout to compare two distinct deal structures.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
33
This slide serves as a reference or bibliography page for a conference presentation.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
34
Uses a before-after framing to justify a strategic pivot in clinical trial focus.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Loop · Before After1 hit
35
Theravance Biopharma | Results Presentation Deck | 35 slidesTheravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Loop · Before After1 hit
01
Slide 1
UBS | Fixed Income Presentation Deck | 44 slidesUBS | Fixed Income Presentation Deck | 44 slides · UBS
Conference presentation Investor relations Beat · Attention1 hit
02
UBS | Fixed Income Presentation Deck | 44 slidesUBS | Fixed Income Presentation Deck | 44 slides · UBS
Conference presentation Investor relations Beat · Attention1 hit
03
UBS | Fixed Income Presentation Deck | 44 slidesUBS | Fixed Income Presentation Deck | 44 slides · UBS
Conference presentation Investor relations Beat · Attention1 hit
04
UBS | Fixed Income Presentation Deck | 44 slidesUBS | Fixed Income Presentation Deck | 44 slides · UBS
Conference presentation Investor relations Beat · Attention1 hit
05
UBS | Fixed Income Presentation Deck | 44 slidesUBS | Fixed Income Presentation Deck | 44 slides · UBS
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
06
The slide uses a four-column layout to delineate business units, each with a strategic objective and supporting bullet points.UBS | Fixed Income Presentation Deck | 44 slides · UBS
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
07
UBS | Fixed Income Presentation Deck | 44 slidesUBS | Fixed Income Presentation Deck | 44 slides · UBS
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
08
The slide uses grouped bar charts to compare UBS and Credit Suisse performance metrics.UBS | Fixed Income Presentation Deck | 44 slides · UBS
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
09
The slide details the composition of the Non-core and Legacy (NCL) perimeter, highlighting the wind-down of Credit Suisse assets.UBS | Fixed Income Presentation Deck | 44 slides · UBS
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
10
The chart shows a projected decline in RWA from 55bn in 2Q23 to 28bn in YE26.UBS | Fixed Income Presentation Deck | 44 slides · UBS
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
11
The slide uses a logic flow from strategic levers (left) to financial targets (right).UBS | Fixed Income Presentation Deck | 44 slides · UBS
Conference presentation Investor relations Beat · SatisfactionLoop · Hypothesis Test1 hit
12
The chart shows a bridge from current state to 2026 exit rate via four strategic levers.UBS | Fixed Income Presentation Deck | 44 slides · UBS
Conference presentation Investor relations Beat · SatisfactionLoop · Hypothesis Test1 hit
13
UBS | Fixed Income Presentation Deck | 44 slidesUBS | Fixed Income Presentation Deck | 44 slides · UBS
Conference presentation Investor relations Beat · SatisfactionLoop · Hypothesis Test1 hit
14
The chart illustrates the impact of the Credit Suisse acquisition on 2Q23 results.UBS | Fixed Income Presentation Deck | 44 slides · UBS
Conference presentation Investor relations Beat · SatisfactionLoop · Hypothesis Test1 hit
15
The slide uses two waterfall charts to explain the financial impact of the Credit Suisse acquisition.UBS | Fixed Income Presentation Deck | 44 slides · UBS
Conference presentation Investor relations Beat · SatisfactionLoop · Hypothesis Test1 hit
16
The slide uses stacked bar charts to illustrate capital structure in absolute terms (bn) and relative terms (%), comparing current status to regulatory requirements.UBS | Fixed Income Presentation Deck | 44 slides · UBS
Conference presentation Investor relations Beat · SatisfactionLoop · Hypothesis Test1 hit
17
The chart shows the reduction of drawn SNB facilities from 120bn to 0 between March and August 2023.UBS | Fixed Income Presentation Deck | 44 slides · UBS
Conference presentation Investor relations Beat · SatisfactionLoop · Hypothesis Test1 hit